
Merida Enters Autoimmune and Allergy Arena With $121M Series A
A new biotech, Merida Biosciences, has launched with $121 million in the bank to advance a new class of precision treatments for autoimmune and allergic diseases. Merida’s therapies are “antibody-like,” according to its Tuesday announcement, aiming for a “ …